Back to News
Market Impact: 0.25
Ultragenyx To Sell Rare Pediatric Disease Priority Review Voucher For $203 Mln
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million. The announced transaction provides a significant cash inflow, but the article gives no additional terms or share-market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
RARE0.55
More News
- Anthropic's third-quarter revenue is said to hit $16.8 billion ahead of IPO
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Netwealth stock sliding today?
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment
- Bending Spoons Stock Soars on Berkshire’s Increased Stake